Advances in medicine come from new ideas developed through clinical trials and research. At Renown Health, we conduct hundreds of clinical trials (also called research trials or research studies) in our ongoing effort to discover and deliver more effective treatments.

Our goal is to translate discoveries made in the laboratory to the patients who will benefit from them, and to do it as quickly as possible.

Select a category from the list below, and contact us at 775-982-5050 for oncology studies or 775-982-2976 for all other studies for more thorough explanation of each study.

Contacting Institutional Review Board (IRB)
Trials that are conducted at Renown Health are reviewed by an Institutional Review Board (IRB), a group of people that reviews human research studies. The Renown Research Office works with several IRBs for research oversight, including:
- University of Nevada, Reno Office of Research Integrity
- Western Institutional Review Board (WIRB)
- Advarra®

To discuss a problem or complaint, or ask about your rights as a research participant call us at 775-982-4635 and we would be happy to connect you with the appropriate IRB official.




RADIANCE II is a randomized, double-blind, sham-controlled, single cohort study designed to demonstrate the effectiveness and safety of the Paradise Renal Denervation System in hypertensive subjects.  The ReCor Medical Paradise® Renal Denervation System (Paradise System) is a catheter-based system that delivers ultrasound energy to thermally ablate and disrupt the renal efferent and afferent sympathetic nerves while sparing the renal arterial wall. The goal of renal nerve ablation is to achieve a reduction in sympathetic over-activity with the resultant effect of reducing systemic arterial blood pressure (BP), and mitigating resultant end organ damage.  Subjects will be followed for 36 months post procedure.  Included in the follow up visits are renal ultrasound, renal CT-Angiogram, lab, office blood pressure, drug escalation if needed, and 24 hour ambulatory blood pressure monitoring.​​


RADIANCE-HTN is a randomized, double-blind, sham controlled, designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in hypertensive subjects. The purpose of the RADIANCE-HTN study is to demonstrate the ability of the Paradise System to effectively reduce systolic daytime ambulatory BP (ABP) in hypertensive subjects with uncontrolled, treatment resistant hypertension despite at least three antihypertensive drugs of different classes including a diuretic. In addition the study is designed to document the safety profile of the Paradise System in all treated subjects. The Primary Efficacy endpoint will be collected at 2 months post procedure. Subjects will be followed for 3 years with visits once per month for 6 months, at 12 months, 24 and 36 months post procedure. Follow up surveillance will include CT, renal ultrasound, labs, office blood pressures and 24 hour ambulatory monitoring.


GUIDE-HF is a prospective, multi-center, randomized, dual arm, single-blind, controlled, interventional clinical trial intended to demonstrate the effectiveness of the CardioMEMS™ HF System to manage heart failure in an expanded patient population outside of the present indication. The CardioMEMS HF System consists of a pressure sensor implanted into the pulmonary artery and an external electronics that transmits pulmonary artery pressure measurements to a secure website. Healthcare professionals are able to access these measurements to guide individualization of medical management for their patients with chronic HF with the goal of reducing recurrent HFH and symptoms of heart failure. The study population will consist of 3600 people >18 years of age; New York Heart Association Class II, III, or IV; with either a heart failure hospitalization(HFH) within the last year or an elevated NTproBNP/BNP lab value within the last 30 days. After device implantation, subjects will be followed for 12 months through phone calls and clinic visits at 6 &12 months.

Paraglide HF

Paraglide HF is a multicenter, randomized, double-blind, double-dummy, parallel group, active controlled Phase IIIb drug study to evaluate the effectof sacubitril/valsartan versus valsartan on changes in NTproBNP and outcomes, safety, and tolerability in HFpEF patients (left ventricular ejection fraction (LVEF) > 40%) with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization and initiated in-hospital or within 30 days post-discharge (PARAGLIDE-HF). The purpose of the study is to assess the effect of sacubitril/valsartan on NTproBNP lab values from baseline to 4 and 8 weeks; changes in renal function; HF hospitalizations and urgent HF visits. The study population will consist of 800 male and female patients ≥ 40 years of age. Medication dosing will be 2 pills twice a day with duration of treatment from 8 weeks (minimum) to approximately 20 months.

Envisage-TAVI AF

Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortiv Valve Implantation in Atrial Fibrillation.

This is a multinational, multicenter, prospective, randomized, open-label study. Comparing Edoxaban with VKA in subjects with Atrial Fibrillation aged 18 and older having undergone TAVI. Participation will last approximately up to 3 years.



Perspective is a phase 3 multicenter, randomized, double-blind, active-controlled study to evaluate the effects of valsartan/sacubitril compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction. The Primary Objective is to evaluate the effects of valsartan/sacubitril compared to valsartan on cognitive function over 3 years in patients with HFpEF as assessed by the CogState cognitive assessment battery. The study population will consist of 520 patients ≥ 60 years of age with chronic symptomatic HF New York Heart Association class II-IV and left ventricular ejection fraction > 40%.


GalacticHF is a Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction(HFrEF) . The purpose of the study is to assess the ability of omecamtiv mecarbil (OM) compared with placebo when added to the normal standard of care in Heart Failure patients to reduce heart failure hospitalizations, improve symptoms , and prolong survival. Study population is adults age 18 to 85 years with a history of chronic HF. Participation is approximately from 24 to 48 months.


A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Extension

The purpose of this Phase 2 research study is to evaluate how safe, tolerable, and effective XEN1101 is for reducing the frequency (number) of focal seizures in patients when taken daily with other anti-epileptic drugs. It is designed as a randomized, double-blind, placebo-controlled, multicenter study, that evaluates the investigational drug called XEN1101 in adult patients aged 18 to 75 years diagnosed with focal epilepsy. The duration of the study is 20 weeks; after screening, patients will have 8 weeks of baseline to assess frequency of seizures, followed by 8 weeks of treatment and a 4-week post treatment follow-up period. In order to be included in the study, patients must already be treated with a stable dose of 1 to 3 allowable current anti-epileptic drugs for at least one month prior to screening, during baseline, and throughout the duration of the study.

Follow-up Imaging After Thrombolysis - Neurology

The purpose of the FIAT study is to investigate whether undergoing a head CT scan, changes clinical care and health outcomes among adults who have had a stroke. Patients are randomized to either undergo a head CT scan (standard of care) or to the research group which will not receive the head CT scan. This study's goal is to provide information which will reduce treatment burdens for patients and healthcare providers, reduce the radiation that stroke patients are exposed to during CT scans, and improve patient outcomes. The study population includes adults 18 years or older who received IV thrombolytics for an acute ischemic stroke and have an NIHSS less than 10 after administration of thromobolytics. Patients participate in this study for 3 months; in-patient procedures described above and a 3-month follow-up call. 


As the largest healthcare system in northern Nevada and eastern California, and in partnership with the National Cancer Institute and the Nevada Cancer Research Foundation, we have access to dozens of open clinical trials.

We provide education and guidance to help patients make decisions about their care and treatment. Our specially trained research nurses and coordinators will help you understand the process and explain what to expect with each visit. We are committed to bringing the highest quality of cancer care to you and your loved ones.


Renown Health MyAIRVO™2 COPD Pilot

The purpose of this study is to evaluate the effectiveness, and economic value of adding a High Flow Nasal Cannula (HFNC) apparatus, the myAirvo™2 device, to current therapy in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The utilization of myAirvo™2 will help us learn whether this device can improve health-related quality of life (HRQoL). Patients with moderate to severe COPD with 2 outpatient claims, 2 or more COPD exacerbations or 1 COPD related ER visit, in previous calendar year are eligible to participate in this study. The study is approximately 1 year long; with a visit at 2 months, 4 months, 6 months, 9 months and 12 months from first visit.


Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 - Infectious Disease

This expanded access program will provide access to investigational convalescent plasma for patients 18 years and older in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. Following registration on the protocol and provision of informed consent, patients will be transfused with one unit of ABO compatible convalescent plasma obtained from an individual who has recovered from documented infection with SARS-CoV-2. Safety information collected will include serious adverse events judged to be related to the administration of convalescent plasma. Other information to be collected retrospectively will include patient demographics, acute care facility resource utilization (total length of stay, days in ICU, days intubated, and survival to discharge from an acute care facility.

Screening for SARS-CoV-2 Immune Plasma - Infectious Disease

The purpose of this study is to collect blood samples from adults who have recovered from the COVID-19 virus to measure their immune system response and to evaluate if they might be able to donate your blood plasma to treat others who have COVID-19. We hope to learn about the body's immune response to COVID-19 over time, and also assist individuals who are interesting in donating plasma through that process. Participation in this research will last about 1 year, with blood collection over time (up to 5 times over 1 year) to look at how antibodies and other immune responses change over time.

Study of the Treatment and Outcomes in critically ill Patients with COVID-19 (STOP-COVID) - Infectious Disease

STOP-COVID is a multicenter observational study of the clinical features and outcomes of critically ill patients with COVID-19 admitted to intensive care units (ICUs) across the U.S. The study population includes adults 18 years and older who have tested positive for COVID-19 and were admitted into an ICU for treatment. De-identified data is collected up to 14-days after admission to the ICU. Our goals are to determine the independent risk factors for hospital mortality and acute organ injury, and to identify treatment strategies associated with improved survival.

A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia – Infectious Disease

This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe COVID-19 pneumonia. Participants must be 18 years or older, and participation in this study will last a duration of 60 days. Participants will be randomized to receive either 8 mg/kg or 4 mg/kg of TCZ, a drug designed to reduce extreme immune system responses to infection seen among COVID-19 patients.